Skip to main content

Table 3 Tumor response at 6 months in the two treatment groups

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Tumor response Sorafenib group
(n = 40)
TACE + sorafenib group
(n = 48)
P
CR, n (%) 2 (5.00%) 3 (6.25%) 1.000
PR, n (%) 3 (7.50%) 6 (12.50%) 0.502
SD, n (%) 18 (45.00%) 18 (37.50%) 0.476
PD, n (%) 17 (42.50%) 21 (43.75%) 0.906
OR, n (%) 5 (12.50%) 9 (18.75%) 0.425
  1. CR complete response, OR overall response (CR + PR), PD progressive disease, PR partial response, SD stable disease